S. Hafeez

Royal Marsden NHS Foundation Trust

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Robert Huddart

Royal Marsden Hospital

H. McNair

Institute of Cancer Research

Emma Hall

Institute of Cancer Research

V.N. Hansen

Rigshospitalet

Susan Lalondrelle

Royal Marsden NHS Foundation Trust

K. Warren-Oseni

Royal Marsden NHS Foundation Trust

Rebecca Lewis

Institute of Cancer Research

Ann Henry

Leeds Teaching Hospitals NHS Trust

Ananya Choudhury

The Christie NHS Foundation Trust

Vincent Khoo

Royal Marsden NHS Foundation Trust

Cooperative Institutions

Institute of Cancer Research

144

Royal Marsden NHS Foundation Trust

140

Royal Marsden Hospital

University College London

National Health Service

Radboud University Nijmegen

University Medical Center Utrecht

Radboud University Medical Center

Cancer Research UK

Guy's and St Thomas' NHS Foundation Trust

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial

Clinical Oncology (2023)

Robert Huddart S. Hafeez Mohd Azahadi Omar R. Alonzi Alison Birtle

Concomitant

10.1016/j.clon.2023.05.002

Cite

Citations (10)

Radium-223 for the treatment of prostate cancer

Expert Opinion on Investigational Drugs (2013)

S. Hafeez Christopher Parker

Introduction: Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer (CRPC). Until recently, treatment options have been limited, but now six drugs are known to extend life expectancy, with docetaxel the current standard first-line cytotoxic therapy. Phase III studies have also shown a survival advantage for sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223. Radium-223 is unique among these agents, as the only bone-directed therapy shown to prolong survival in CRPC.

Cabazitaxel

Radium-223

Enzalutamide

Abiraterone

Abiraterone acetate

Radium

10.1517/13543784.2013.761974

Cite

Citations (16)

Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy).

Journal of Clinical Oncology (2014)

Robert Huddart Fiona McDonald S. Hafeez K. Warren-Oseni Helen Taylor

291 Background: Prospective study assessing the safety of dose escalation in the treatment of localised muscle-invasive bladder cancer using image-guided adaptive radiotherapy (RT) with a reduced high-dose tumour volume. Methods: Radical RT was planned and delivered in 3 phases. Phase I was delivered to the empty whole bladder (10Gy 5#). Bladder variation assessed on phase I daily imaging was used to determine the adaptive approach for phase III (composite volume or plan of the day). Phase II was delivered to a tumour boost volume on a partially filled bladder (18Gy 9# if normal tissue dose-constraints were met, or to 14Gy 7# if they were not). The adaptive phase III (40Gy 20#) was delivered to the empty whole bladder. The primary endpoint was late RTOG toxicity. Results: Of the twenty-six patients recruited to 68Gy, 20 patients met the normal tissue constraints for dose escalation. For the phase III adaptive technique, 14 patients were treated with a composite volume approach and 12 with a plan of the day. At median follow-up of 24 months, 13 (65%) dose escalated patients remain alive and disease free. Within this dose cohort there has been 1 muscle invasive local recurrence, 1 superficial recurrence and 1 patient has developed metastases. 5 patients in the dose-escalated group have died; 3 from cardiac events, 1 from hospital acquired pneumonia and 1 from metastatic bladder cancer. 1 patient in the dose-escalated group has experienced grade 3 late toxicity (cystitis) occurring 24.6 months after the end of radiotherapy. Conclusions: Image-guided adaptive RT techniques with reduced high-dose volume allow tumour dose-escalation. Toxicity data to date suggest tolerability of 68Gy. Local disease control rates are promising. Trial recruitment continues at 70Gy using intensity modulated radiotherapy technique to deliver a simultaneous integrated boost. Clinical trial information: 7653.

Clinical endpoint

10.1200/jco.2014.32.4_suppl.291

Cite

Citations (7)

The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer

Radiotherapy and Oncology (2015)

Anne Vestergaard S. Hafeez L.P. Muren Simeon Nill Morten Høyer

10.1016/j.radonc.2015.11.003

Cite

Citations (52)

PO-0734: Assessing response to radiotherapy with diffusion weighted MRI (DW-MRI) in muscle invasive bladder cancer (MIBC)

Radiotherapy and Oncology (2014)

S. Hafeez Myeong Ju Koh Aslam Sohaib Robert Huddart

10.1016/s0167-8140(15)30852-5

Cite

Citations (3)

Outcomes of Selective Organ Preservation with Neoadjuvant Chemotherapy in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Bladder: The Royal Marsden Experience

Clinical Oncology (2013)

S. Hafeez Robert Huddart

Gold standard (test)

Standard of care

Neoadjuvant Therapy

10.1016/j.clon.2012.12.014

Cite

Citations (0)

P013 Outcomes of selective bladder preservation with neo-adjuvant chemotherapy in muscle invasive transitional cell carcinoma (TCC)

European Urology Supplements (2012)

S. Hafeez Robert Huddart

Adjuvant Chemotherapy

10.1016/s1569-9056(13)60393-0

Cite

Citations (0)

Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience

BMC Medicine (2015)

S. Hafeez M. Singhera Robert Huddart

Down syndrome is the most common chromosomal disorder in humans as well as the most common cause of inherited intellectual disability. A spectrum of physical and functional disability is associated with the syndrome as well as a predisposition to developing particular malignancies, including testicular cancers. These tumours ordinarily have a high cure rate even in widely disseminated disease. However, individuals with Down syndrome may have learning difficulties, behavioural problems, and multiple systemic complications that have the potential to make standard treatment more risky and necessitates individualized approach in order to avoid unacceptable harm. There is also suggestion that tumours may have a different natural history. Further, people with learning disabilities have often experienced poorer healthcare than the general population. In order to address these inequalities, legislation, professional bodies, and charities provide guidance; however, ultimately, consideration of the person in the context of their own psychosocial issues, comorbidities, and possible treatment strategies is vital in delivering optimal care. We aim to present a review of our own experience of delivering individualized care to this group of patients in order to close the existing health inequality gap.

10.1186/s12916-015-0386-4

Cite

Citations (11)

PO-0864 Normal tissue sparing with diffusion weighted MRI informed tumour boost in bladder radiotherapy

Radiotherapy and Oncology (2019)

Kannie W. Y. Chan K. Warren-Oseni Hassan Abdel‐Aty Alex Dunlop D. McQuaid

10.1016/s0167-8140(19)31284-8

Cite

Citations (6)

Remote training solutions for complex intervention trials

Trials (2015)

Rebecca Lewis S. Hafeez H. McNair J. Illambas Charlotte Friend

Background Delivering training to participating sites is an essential part of successful trial setup especially when new techniques, treatments or technologies are involved. RAIDER is a multicentre (> 30 NHS Trusts) phase II trial of complex radiotherapy for muscle invasive bladder cancer. The radiotherapy techniques were developed at a single UK NHS site and in addition to written materials ideally require demonstration using the relevant radiotherapy planning and imaging software, only available at the experienced site. Rather than arranging a series of visits from key participating site personnel (Principal Investigator (PI) and research radiographers), a virtual meeting plan was developed.

10.1186/1745-6215-16-s2-p194

Cite

Citations (1)